Regulation of arterial thrombolysis by plasminogen activator inhibitor- 1 in mice

Circulation

Volumn 97, Issue 10, 1998, Pages 1002-1008

  Farrehi, Peter M ^b   Keith Ozaki, C Keith ^b   Carmeliet, Peter ^b   Fay, William P ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

Carotid arteries; Plasminogen activators; Thrombolysis; Thrombosis

Indexed keywords

FERRIC CHLORIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOT LYSIS; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; HISTOPATHOLOGY; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 0345725987     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.10.1002     Document Type: Article

References (55)

1. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
2. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991;78:3114-3124.
3. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT, Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897-902.
4. Boehrer JD, Glamann DB, Lange RA, Willard JE, Brogan WC, Eichhorn EJ, Grayburn PA, Anwar A, Hillis LD. Effect of coronary angioplasty on late potentials one to two weeks after acute myocardial infarction. Am J Cardiol. 1992;70:1515-1519.
5. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WK, Vahanian A, Simoons ML, Morrs D, Betriu A, Califf RM, Ross AM, GUSTO-1 Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete inferct artery reperfusion. Circulation. 1995;91: 1923-1928.
6. Plow EF, Herren T, Redlitz A, Miles LA. Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J. 1995;9:939-945.
7. Levi M, Biemond BJ. van Zonneveld AJ. Wouter Ten Cate J. Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation. 1992;85:305-312.
8. Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res. 1993;72:413-421.
9. Torr-Brown SR, Sobel BE. Plasminogen activator inhibitor is elevated in plasma and diminished in platelets in patients with diabetes mellitus. Thromb Res. 1994;75:473-477.
10. Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR, Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor-1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombosis. Blood. 1993;81:1290-1299.
11. Stringer HAR, van Sweiten P, Heijnen H, Sixma J, Pannekoek H, Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Arterioscler Thromb. 1994;14:1452-1458.
12. Kunitada S, Fitzgerald G, Fitzgerald D. Inhibition of clot lysis and decreased binding of tissue-type plasminogcn activator as a consequence of clot retraction. Blood. 1992;79:1420-1427.
13. Bajzar L, Tracy PB. Platelet factor V(a) is responsible for the majority of the antifibrinolytic effect of platelets. Blood. 1995;86:74a. Abstract.
14. Fay WP, Murphy JG, Owen WG. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi. Arterioscler Thromb Vasc Biol. 1996;16:1277-1284.
15. Doevendans PA, Hunter JJ, Lembo G, Wollert KC, Chien KR. Strategies for studying cardiovascular diseases in transgenic and gene-targeted mice. In: Monastersky GM, Robl JM, eds. Strategies in Transgenic Animal Science, Washington, DC: American Society for Microbiology: 1995:107-144.
16. Chien KR. Molecular medicine in genetically engineered animals: series introduction. J Clin Invest. 1996;98(suppl):S1.
17. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan R. Plasminogen activator inhibitor-1 gene deficient mice, I: generation by homologous recombination and characterization. J Clin Invest. 1993;92:2746-2755.
18. Fay WP, Shapiro AD, Shih JL, Schlecf RR, Ginsburg D. Brief report: complete deficiency of plasminogen activator inhibitor type-1 due to a frame-shift mutation. N Engl J Med. 1992;327:1729-1733.
19. Fay WP, Parker AC, Condrey LR. Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 1997;911:204-208.
20. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D. Simon RH. Bleomycin-induced pulmonary fibrosis in transonic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 1996;97:232-237.
21. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thrombosis Res. 1990;60:269-280.
22. Hayat MA. Principles and Techniques of Electron Microscopy. Boca Raton, Fla: CRC Press; 1989.
23. Liang KY, Zeger SL, Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
24. Jang I, Gold H, Ziskind A, Fallon J, Holt R, Leinbach R, May J, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation. 1989;79:920-928.
25. Henry RL. Leukocytes and thrombosis. Thromb Diath Haemorrhagica. 1965;13:35-46.
26. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation. 1991;83(suppl IV):IV-3-IV-14.
27. Fujii S, Sobel BE. Induction of plasminogen activator inhibitor by products released from platelets. Circulation. 1990;82:1485-1493.
28. Reilly CF, Fujita T, Mayer EJ, Siegfried ME. Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. Arterioscler Tromb. 1991;11:1276-1286.
29. Marsh JJ, Konopka RG, Lang IM, Wang HY, Pedersen C, Chiles P, Reilly CF. Moser KM. Suppression of thrombolysis in a canine model of pulmonary embolism. Circulation. 1994;90:3091-3097.
30. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasmmogen activator inhibitor-1 genedeficient mice, II: effects on hemostasis, thrombsis, and thrombolysis, J Clin Invest. 1993;92:2756-2760.
31. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation. 1995;91:1175-1181.
32. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1 dependent and independent mechanisms. Blood. 1994;83:351-356.
33. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's Nature. 1993;362:801-809.
34. Eitzman DT, Nabel EG, Gordon D, Fay WP, Rekhter MD, Ginsburg D. Atherosclerosis in transgenic mice that either overexpress or lack the murine plasminogen activator inhibitor-1 gene. Circulation. 1996:94(suppl I):I-460. Abstract.
35. Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor-1 : development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood. 1987;70:1645-1653.
36. Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res. 1984;33:323-530.
37. Stassen JM, Lijnen HR, Kieckens L, Collen D. Small animal thrombosis models for the evaluation of thrombolytic agents. Circulation. 1991;83: 65-79.
38. Philip RB, Francey I, Warren BA. Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK 744 in a rat model of arterial thrombosis. Haemostasis. 1978;7:282-293.
39. Weichert W, Breddin HK. Effect of antibiotics on laser-induced thrombus formation in rat mesenteric arterioles. Haemostasis. 1989;19:224-228.
40. Matsuno H, Uematsu T, Nagashima S, Nakashima M. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Methods. 1991;25:303-317.
41. Davidson SF, Brantley SK, Talbot PJ, Das SK. A functional model of microvascular thrombosis. Plast Reconstr Surg. 1990;86:579-581.
42. Lenfors S, Marberg L, Wikstrom S, Jonsson U, Eriksson AW, Gustafsson D. A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyte-rich tail: thrombolysis experiments with specific thrombin inhibition. Blood Coagul Fibrinolysis. 1993;4:263-271.
43. Palabrica T, Liu A, Aronovitz M, Furie B, Lawn R. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med. 1995;1:256-259.
44. Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, Acland R, Hams EN. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost. 1994;71:670-674.
45. Balla G, Vercellotti GM, Eaton JW, Jacob HS. Iron loading of endothelial cells augments oxidant damage. J Lab Clin Med. 1990;116:546-554.
46. Rote WE, Oldesthulte GL, Dempsey EM, Vlasuk GP, Evaluation of a novel small protein inhibitor of the blood coagulation factor VIIa/tissue factor complex in animal models of arterial and venous thrombosis. Circulation. 1996;94(suppl I):1-695. Abstract.
47. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594-599.
48. Carmeliet P, Moons L, Stassen JM, De Mol M, Bouche A, van den Oord JJ, Kockx M, Collen D. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol. 1997;150:761-776.
49. Carmeliet P, Collen D. Evaluation of the plasminogen/plasmin system in transgenic mice. Fibrinolysis. 1994;8:269-276.
50. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 1995;9:794-807.
51. Bugge TH, Suh TT, Flick MJ, Daugherty CC, Romer J, Solberg H, Ellis V, Dano K, Degen JL. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem. 1995;270:16886-16894.
52. Zheng X, Saunders TL, Clamper SA, Samuelson LC, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci U S A. 1995;92:12426-12430.
53. Heckel JL, Sandgren EP, Degen JL, Halmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell. 1990;62:447-456.
54. Suh TT, Holmback K, Jemen NJ, Daugherty CC, Small K, Simon DI, Potter SS, Degen JL. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995;9:2020-2033.
55. Ploplis V, Carmeliet P, Vazirzadeh S, Vlaenderen IV, Moons L, Plow E, Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation. 1995;92:2585-2593.